Researchers at AstraZeneca, Viela Bio, Gilead Sciences, Antidote Therapeutics Inc., and at SoseiHeptares report on a new small molecule compound to treat RA.
As a first result of the trilogue on the €100m+ Horizon Europe programme, MEPs backed the backbone of the EU’s future research and innovation programme.
Pilot routine tests with the vasoactive biomarker bio-ADM confirm clinical test results. Medical leaders back actionable utility of the marker in medical decision-making in septic shock and congestive heart failure.
https://european-biotechnology.com/wp-content/uploads/2024/04/BiotechPharma.png9561702Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-04-18 06:19:002019-04-18 06:19:00Biotechpharma UAB expanding production
Kiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy.
Researchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome.
Biomanufacturing – either for production of biologics or bio-based everyday products – has traditionally suffered from the unpredictably variable response of production cell lines to external stimuli. Synthetic biology groups now wish to create a network of biofoundries that aim to establish reproducibility standards from process design to product purification and – in the long term – intend to switch from cell-based to cell-free bioproduction.
IGEM Therapeutics, an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining IGEM as a Non-Executive Chairman effective immediately.
https://european-biotechnology.com/wp-content/uploads/2024/04/davidchiswellsml.png423423h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-04-12 15:39:002019-04-12 15:39:00IGEM Therapeutics appoints Dr David Chiswell
A novel strategy against rheumatoid arthritis
Latest NewsResearchers at AstraZeneca, Viela Bio, Gilead Sciences, Antidote Therapeutics Inc., and at SoseiHeptares report on a new small molecule compound to treat RA.
US patent office grants Charpentier CRISPR patent
Latest NewsThe US Patent Office has granted the Charpentier/Doudna key CRISPR patent, which was previously involved in an interference proceeding.
European Parliament greenlights Horizon Europe priorities
Latest NewsAs a first result of the trilogue on the €100m+ Horizon Europe programme, MEPs backed the backbone of the EU’s future research and innovation programme.
Blood routine testing in sepsis and AHF ahead
BackgroundPilot routine tests with the vasoactive biomarker bio-ADM confirm clinical test results. Medical leaders back actionable utility of the marker in medical decision-making in septic shock and congestive heart failure.
Biotechpharma UAB expanding production
Latest NewsLituanian CDMO Biotechpharma UAB has invested €50m in order to expand its production capacity to 5000 litres.
Kiadis Pharma NV to acquire CytoSen Therapeutics, Inc.
Latest NewsKiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy.
Treating diabetes by mimicking gut bacteria effects
Latest NewsResearchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome.
Immunic lists at Nasdaq
Latest NewsChronic inflammatory disease company Immunic Therapeutics starts Nasdaq-trade following merger with Vital Therapies.
Bioengineers to standardise biomanufacturing
BackgroundBiomanufacturing – either for production of biologics or bio-based everyday products – has traditionally suffered from the unpredictably variable response of production cell lines to external stimuli. Synthetic biology groups now wish to create a network of biofoundries that aim to establish reproducibility standards from process design to product purification and – in the long term – intend to switch from cell-based to cell-free bioproduction.
IGEM Therapeutics appoints Dr David Chiswell
AppointmentsIGEM Therapeutics, an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining IGEM as a Non-Executive Chairman effective immediately.